SBIR/STTR Research Award
Absorbable and Low-Cost Radioseeds for Malignant Tumors
Award amount
$146,461Program and phase
SBIR · Phase IAward year
2006Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- XL Sci Tech Inc
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- H1Z8MEH658H9
- Solicitation number
- PHS2006-2
- Topic code
- Not reported
Research abstract
DESCRIPTION (provided by applicant): The objective of this Phase I research is to demonstrate the feasibility of creating timed-bioabsorbable Pd-103 seeds for the treatment of prostate tumors. Timed- bioabsorbable seeds have the combined benefits of titanium seeds, high dose rate temporary seeds, external beam radiation and other treatment options. In addition, timed-bioabsorbable seeds potentially offer desirable post-treatment options, total bioabsorption of the implants and the lowest overall treatment cost. The specific aims of this proposed Fast Track Phase I research are to (1) identify absorbable matrices that have appropriate intrinsic bioabsorption rates and are suitable for engineered control of bioabsorption profiles; (2) determine seed dimension for optimal imaging; (3) control the bioabsorption such that the cumulative Pd-103 radioactivity leakage from seeds is 1% or less and the complete bioabsorption of seed matrices is estimated within 2 years; (4) determine and recommend optimal matrix chemistry and bioabsorption engineering conditions for in-depth studies of Pd-103 leakages and bioabsorption profiles in the Fast-Track Phase II; and (5) demonstrate the biocompatibility for selected timed-bioabsorbable seeds in vitro using ISO methods. Achieving key and measurable milestones set in Phase I will ensure successful completion of the proposed Fast Track Phase II, leading to high impact bioabsorbable seeds for the treatment of prostate tumors and other malignant tumors.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- PET Enabled Y-90 Microspheres for Radioembolization of Liver Tumors
- Radioactive Stents for Brachytherapy of Esophageal Cancers
- PET Enabled Microspheres for Radioembolization of Liver Tumors
- Enzyme Replacement Therapy for Sanfilippo A Lysosomal Rare Disease
- A Novel Brachytherapy Agent for GBM